Panitumumab monotherapy compared with cetuximab and irinotecan combination therapy in patients with previously treated KRAS wild-type metastatic colorectal cancer

Current Oncology

Volumn 20, Issue 6, 2013, Pages 326-332

  Kennecke, H ^a   Chen, L ^b   Blanke, C D ^a   Cheung, W Y ^a   Schaff, K ^a   Speers, C ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Anti EGFR; Cetuximab; Chemotherapy; Irinotecan; Mcrc; Multivariate analysis; Panitumumab; Survival

Indexed keywords

CETUXIMAB; IRINOTECAN; PANITUMUMAB;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS RESECTION; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROSPECTIVE STUDY; QUALITY OF LIFE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84890098854     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.20.1600     Document Type: Article

References (21)

1. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (brite). J Clin Oncol 2008;26:5326-34.
2. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009;27:3677-83.
3. Renouf DJ, Lim HJ, Speers C, et al. Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis. Clin Colorectal Cancer 2011;10:97-101.
4. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase iii trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (folfox4) versus folfox4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the prime study. J Clin Oncol 2010;28:4697-705.
5. Van Cutsem E, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011-19.
6. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
7. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-71.
8. Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 mrc coin trial. Lancet 2011;377:2103-14.
9. Tveit K, Guren T, Glimelius B, et al. Randomized phase iii study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as firstline treatment of metastatic colorectal cancer: The nordic vii study (NCT00145314), by the Nordic Colorectal Cancer Biomodulation Group [abstract 365]. J Clin Oncol 2011;29:. [Available online at: http://meetinglibrary.asco.org/ content/70979-103; cited October 19, 2013]
10. Peeters M, Price TJ, Cervantes A, et al. Randomized phase iii study of panitumumab with fluorouracil, leucovorin, and irinotecan (folfiri) compared with folfiri alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:4706-13.
11. Sobrero AF, Maurel J, Fehrenbacher L, et al. epic: phase iii trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:2311-19.
12. Seymour MT, Brown SR, Middleton G, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (piccolo): a prospectively stratified randomised trial. Lancet Oncol 2013;14:749-59.
13. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
14. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
15. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
16. Hess GP, Wang PF, Quach D, Barber B, Zhao Z. Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in U.S. medical oncology practice. J Oncol Pract 2010;6:301-7.
17. Price TJ, Peeters M, Kim TW, et al. aspecct: a randomized, multicenter, open-label, phase 3 study of panitumumab (pmab) vs cetuximab (cmab) for previously treated wild-type (wt) KRAS metastatic colorectal cancer (mcrc). In: Proceedings of the European Cancer Congress 2013; Amsterdam, Netherlands; September 27-October 1, 2013.
18. Roca J, Alonso V, Pericay C, et al. Cetuximab given every 2 weeks (q2w) plus irinotecan, as feasible option, for previously treated patients (pts) with metastatic colorectal cancer (mcrc) [abstract 15122]. J Clin Oncol 2008;26:. [Available online at: http://meeting.ascopubs.org/cgi/content/abstract/26/15_ suppl/15122; cited October 28, 2013]
19. Pfeiffer P, Nielsen D, Bjerregaard J, Qvortrup C, Yilmaz M, Jensen B. Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol 2008;19:1141-5.
20. Martin-Martorell P, Rosello S, Rodriguez-Braun E, Chirivella I, Bosch A, Cervantes A. Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase ii single institution trial. Br J Cancer 2008;99:455-8.
21. BC Cancer Agency (bcca). BCCA Protocol Summary for Curative Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, Capecitabine and Radiation Therapy. Vancouver, BC: bcca; 2013 [Available online at http:// www.bccancer.bc.ca/NR/rdonlyres/C0A8933B-3AAD-4EBAA95C-4552A0A060C9/63672/GICART_Protocol_1May2013. pdf; cited May 30, 2013).